Case report

Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases

Majdouline Boujoual1,², Ihsan Hakimi2, Farid Kassidi2, Youssef Akhouda², Nawal Sahef³, Adil Rkiouak³, Mohamed Allaaou³, Hafsa Chahdi¹, Mohamed Oukabi4, Jaouad Kouch², Driss Rahali Moussaoui², Mohamed Dehayni²

¹Department of Gynecology-Obstetric, University of Medicine Tangier, Military Training Hospital Med V, Rabat, Maroc, ²Department of Gynecology-Obstetric, Military Training Hospital Med V, Rabat, Maroc, ³Department of Internal Medicine, Military Training Hospital Med V, Rabat, Maroc, ⁴Department of Pathology, Military Training Hospital Med V, Rabat, Maroc

Corresponding author: Majdouline Boujoual, Department of Gynecology-Obstetric, Military Training Hospital Med V, Hay Riyad, Rabat, Maroc

Key words: Paraneoplastic syndrome, ovarian teratoma, diagnosis, management

Received: 05/04/2015 - Accepted: 06/04/2016 - Published: 25/06/2016

Abstract

Paraneoplastic syndromes are a heterogeneous group of clinical and biological manifestations caused by underlying neoplasms. They can reveal ovarian teratoma which express neuroendocrine proteins, or contain mature or immature neural tissue inducing an autoimmune response. The etiological investigation is then crucial to early identification of the tumor in order to optimize the prognosis and to limit neurological sequelae. In case of ovarian teratoma, management is essentially based on surgical resection sometimes associated with immunotherapy. We report two new cases of ovarian teratoma revealed by paraneoplastic syndromes in young and menopausal woman.

Pan African Medical Journal. 2016; 24:161 doi:10.11604/pamj.2016.24.161.6743

This article is available online at: http://www.panafrican-med-journal.com/content/article/24/161/full/

© Majdouline Boujoual et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Paraneoplastic syndromes are a heterogeneous collection of manifestations caused by underlying neoplasm [1]. It can proceed, occur with, or develop after a malignancy [2], affecting patients of all ages [3] and are often misdiagnosed [4]. Actually, major advances in the management include the discovery and improved characterization of these syndromes, detection of new anti-neuronal antibodies and the use of CT and PET scan to reveal the associated tumors at an early stage [5] in order to improve prognosis [6]. Thus, awareness of paraneoplastic syndromes is important for various practitioners, including both neurologists and gynecologists [1].

**Patient and observation**

**Case N°1:**

A 60-year-old menopausal female admitted to internal medicine service for myalgia and generalized weakness with weight loss of 8 kg in 2 months. Her clinical examination found a myogenic syndrome with hypotonia, muscle weakness predominant in the lower limbs and associated to functional impairment with dyspnea stage III. Biological investigation showed cytolyis with CPK: 9000 U/L, LDH: 731 U/L, AST: 179 U/L, ALT: 164 U/L, and TP: 87%. Serological examination was negative including viral hepatitis A, B, C, HIV, EBV and CMV. Thyroid and parathyroid function, as immunological tests (anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-LKM1) were all normal. Tumor markers were increased 2x normal and CA15-3 was 5x normal. Liver biopsy showed chronic hepatitis with a score of Metavir A1F0 without injury or tumor specific inflammatory. A paraneoplastic polymyositis was so suspected. However, electromography and muscle biopsy didn’t show any sign of myositis. Thoraco abdominopelvic CT objectified infra centimetric pulmonary nodules with left dermoid cyst of the left ovary measuring 36 x 37 mm (Figure 1, Figure 2) which was confirmed by pelvic MRI (Figure 3). Otherwise, bronchoscopy has not objectified suspicious endobronchial lesion, the AFB in sputum was negative and the PET scan confirmed the absence of suspicious pathological fixation. The patient was put under corticosteroids (Prednisone 60mg /day with bolus of Solumedrol), and underwent an exploratory laparotomy with bilateral oophorectomy (Figure 4). Pathological study confirmed a mature dermoid cyst (Figure 5). Postoperatively, biological improvement was achieved despite the persistence of residual muscle deficit. The patient was so put on immunosuppressive treatment with bolus of Endoxan (1g/month) associated with Immunoglobuline (2g/kg/bolus), due to the partial answer (CPK: 1500 U/L). Clinical and biological improvement (resumption of physical activity, autonomy and decreased CPK to 600U/L) were so obtained, and thena relay by immunomodulatory was made after the 6th bolus of Endoxan. The patient has so well evolved, and is currently under corticosteroids regression.

**Case N°2:**

31-year-old female without a past medical history, admitted to neurological service for management of balance and walking disorder lasting for 3 years without signs of intracranial hypertension or other extra neurological signs. Her neurological examination showed a stato-kineti cerebellar syndrome. The cerebral MRI revealed a cerebellar atrophy predominant at vermis without cortical lesion. There was no inflammatory syndrome and cerebrospinal fluid analysis was normal. As part of etiological investigation a thoracoabdominopelvic CT objectified ovarian teratoma measuring 66/53 mm with lobulated contours, fat density and calcifications (Figure 6). The paraneoplastic cerebellar syndrome origin was suspected. The patient underwent laparoscopic cystectomy with biopsy of the contralateral ovary. Histological analysis showed a mature teratoma with skin covering pilosebaceous glands, adipose tissue and brain tissue (Figure 7). Good clinical improvement was obtained after surgery without further therapy.

**Discussion**

**Definition:** Paraneoplastic syndromes (PS) are remote effects of cancer caused neither by invasion of the tumor or its metastases nor by infection, ischemia, metabolic and nutritional deficits, surgery, or other forms of tumor treatment [3]. They may precede the diagnosis [7], or herald the recurrence or a second tumor [3]. Actually, numerous types of paraneoplastic antibodies have been described. Even so, their absence cannot rule out the diagnosis of PS [4].

**Incidence:** PS are rare occurring in less than 0.01% of patients with cancer [4]. Benign teratomas have been associated with a variety of paraneoplastic syndromes including encephalitis, paraneoplastic limbic encephalitis, opsoclonus-myoclonus syndrome, seronegative polyarthritis, tenosynovitis and autoimmune hemolytic anemia [1,8].

**Etiopathogenesis:** PS are believed to be caused by the excessive production or depletion of bioactive substances, growth factors, hormones, or by antigen-antibody interactions with an aberrant host response to various types of cancer [2]. In case of ovarian teratoma, the hypothesis of an autoimmune pathophysiology [9] is supported by its composition of ectoderm; mesoderm and endoderm which could induce an autoimmune response [5,8].

**Diagnosis and identification of the tumor:** Once a paraneoplastic diagnosis has been suspected, rapid identification of the tumor becomes essential but may be difficult since the tumors initially may be histologically small and localized [3,4], as the case of ovarian teratoma [10]. One attitude is restricted to patient interrogation, complete physical examination [11] with additional oriented examination according to specific symptoms as our case of paraneoplastic cerebellar ataxia [11]. In fact, CT and MRI studies demonstrate cerebellar atrophy in the later stages of the disease [4], while the anti-bodies Anti-NMDAR encephalitis are excellent predictors of a better response to immunotherapy [12]. The other attitude includes more a thoracoabdominopelvic CT scan, gastrointestinal tract, and bronchial endoscopic explorations, mammogram, bone marrow biopsy, study of circulating lymphocyte subpopulations, and serum immunolectrophoresis [11]. While whole-body fluoride oxyglucose positron emission tomography is recommended when conventional imaging has failed or lesions are difficult to biopsy [4,5]. If no malignancy is revealed during, surgical exploration and removal of pelvic organs may be warranted, particularly in postmenopausal women [4].

**Treatment:** selection of a treatment plan depends on the clinical severity, rate of progression, and risk of side effects [13].
Tumor removal: Appears to have the best effect on neurological outcome and prevent permanent neurologic sequelae [1]. In fact, it should decrease the antigenic challenge and the risk of tumor growth or metastasis [13].

Immunotherapy: Has been demonstrated to stop the paraneoplastic neurological deterioration including plasma exchange, immunoadsorption, steroids, and intra venous Immunoglobulins [3].

Evolution- prognosis: Early diagnosis is important since patients can recover with immunotherapy and tumor resection [14]. In fact, some neurological PS are monophasic reach a plateau of severity and improve. Others are progressive and fatal [13], leaving the patients severely debilitated within weeks to months. However, slow progression, relapses or a benign course do not exclude the diagnosis [4]. In our cases, the 2nd patient improved dramatically after resection, while the 1st had complete recovery after surgical resection and immunotherapy.

Conclusion

The two cases confirm diagnosis difficulty of this association. In fact, in spite of their rarity, paraneoplastic syndromes can reveal ovarian teratomas. Their management is based on identification and resection of the tumor, optionally combined to immunotherapy. Their prognosis is related to the risk of irreversible sequelae. Hence the interest of their early recognition with clinical, biological and radiological monitoring.

Competing interests

The authors declare no competing interest.

Authors’ contributions

All authors had participated in the management of this case and the realization of this work.

Figures

Figure 1: Thoracic CT revealing infra centimetric pulmonary nodules
Figure 2: Pelvic CT showing dermoid cyst of the left ovary measuring 36 x 37 mm
Figure 3: Pelvic MRI confirming dermoid cyst of the left ovary
Figure 4: Macroscopic appearance of the resected bilateral oophorectomy
Figure 5: Histopathology of mature dermoid cyst (HEX40) showing microscopic appearance of hair sections
Figure 6: Pelvic CT showing ovarian teratoma measuring 66x 53 mm with lobulated contours, fat density and calcifications
Figure 7: Histopathology of mature teratoma with Skin covering with pilosebaceous glands, adipose tissue and brain tissue (HEX50)

References

1. Tillman JA, Raff GJ. Paraneoplastic Limbic Encephalitis Cured with Resection of an Adnexal Mass. JSLS. 2009 Jul-Sep;13(3):433-5. PubMed | Google Scholar
2. Yuste-Chaves M, Unamuno-Pérez P. Cutaneous Alerts in Systemic Malignancy: part I. ActasDermosifiliogr. 2013 May;104(4):285-98. PubMed | Google Scholar
3. De Beukelaar JW, Sillevis Smitt PA. Managing Paraneoplastic Neurological Disorders. Oncologist. 2006 Mar; 11(3):292-305. PubMed | Google Scholar
4. Honnorat J, Antoine JC. Paraneoplasticneurological syndromes. Orphanet J Rare Dis. 2007 May 4;2: 22. PubMed | Google Scholar
5. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 April; 7(4): 327-340. PubMed | Google Scholar
6. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold WHonnorat J, Sillevis Smitt PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuere JJGM. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology. 2011; 18: 19-27. PubMed | Google Scholar
7. Rugiené R, Dadoniene J, Aleknavicius E, Tikūšis R, Distler J, Schett G, Venalis P, Venalis A. Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours. ClinRheumatol. 2011 Mar; 30 (3):373-380. PubMed | Google Scholar
8. Ibarra M, Chou P, Pachman LM. Ovarian Teratoma Mimicking Features of Juvenile Dermatomyositis in a Child. Pediatrics. 2011 Nov; 128(5):e1293-6. PubMed | Google Scholar
9. Zhang H, Zhou C, Wu L, Ni F, Zhu J, Jin T. Are onconeural antibodies a clinical phenomenology in paraneoplastic limbic encephalitis? Mediators Inflamm. 2013; 172986:doi:10.1155/2013/172986. PubMed | Google Scholar
10. Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, Dalmau J. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J NeurolNeurosurg Psychiatry. 2008 March; 79(3): 324-326. PubMed | Google Scholar
11. Amoura Z, Duhaut P, Huong DL et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1279-1282. PubMed | Google Scholar
12. Graus F, Dalmau J. Paraneoplastic neurological syndromes. CurrOpin Neurol. 2012 December ; 25(6): 795-801. PubMed | Google Scholar
13. Pranzatelli MR. Paraneoplastic Syndromes: An Unsolved Murde. Seminars in Pediatric Neurology.2000 (June); 7(2): 118-130. PubMed | Google Scholar
14. Wali SM, Cai A, Rossor AM, Clough C. Appearance of anti-NMDAR antibodies after plasma exchange and total removal of malignant ovarian teratoma in a patient with paraneoplastic limbic encephalopathy. 2011 Mar 24;2011. pii: bcr0220113851 doi:10.1136/bcr.02.2011.3851. PubMed | Google Scholar

**Figure 1:** Thoracic CT revealing infra centimetric pulmonary nodules

**Figure 2:** Pelvic CT showing dermoid cyst of the left ovary measuring 36 x 37 mm

**Figure 3:** Pelvic MRI confirming dermoid cyst of the left ovary
Figure 4: Macroscopic appearance of the resected bilateral oophorectomy

Figure 5: Histopathology of mature dermoid cyst (HEX40) showing microscopic appearance of hair sections

Figure 6: Pelvic CT showing ovarian teratoma measuring 66x 53 mm with lobulated contours, fat density and calcifications
Figure 7: Histopathology of mature teratoma with skin covering with pilosebaceous glands, adipose tissue and brain tissue (HEX50)